Clinical trial evaluating the effectiveness of biocompound IMMUNEPOTENT CRP in the third-molar extraction

Franco‐Molina, Moises Armides; Mendoza‐Gamboa, Edgar; Coronado‐Cerda, Erika Evangelina; Zárate-Triviño, Diana; Arizpe-Coronado, Juan E.; Zapata‐Benavides, Pablo; Ramos-Zayas, Yareellys; Taméz-Guerra, Reyes; Rodríguez‐Padilla, Cristina

doi:10.1080/13102818.2016.1249408

Cited by 6 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although exosome effects vary according to the cell of origin, their potential role in wound healing is novel, especially from a hemoderivative like IMMUNEPOTENT CRP. Previous investigations evaluated possible functions of exosomes isolated from the IMMUNEPOTENT CRP in silico ( Franco-Molina et al, 2016 ) by our research group, proposing a role in biological processes such as wound healing. The study involved both in vitro and in vivo evaluations, revealing distinct cellular responses to ICRP components.…”

Section: Resultsmentioning

confidence: 99%

“…This dialyzate induces antioxidant and anti-inflammatory capacity in human macrophages stimulated with lipopolysaccharides and exhibits a cytotoxic effect in cancer cells in vitro ; this last property is commonly used as a test of potency for extracts ( Franco-Molina et al, 2011 ; Franco-Molina et al, 2021 ). In a clinical trial of third-molar extraction, ICRP action was compared with that of ibuprofen, demonstrating that ICRP exerts an anti-inflammatory effect ( Franco-Molina et al, 2016 ). Our research team has in silico determined some of the varying biological effects of IMMUNEPOTENT CRP derived from both their overall peptide content and the peptides present within exosomes that promote wound healing.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exosomes isolated from IMMUNEPOTENT CRP, a hemoderivative, to accelerate diabetic wound healing

García Coronado,

Franco Molina,

Zárate Triviño

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The increasing risk of amputation due to diabetic foot ulcer calls for new therapeutic options; for that, we determined the role of IMMUNEPOTENT CRP (ICRP) and its parts in the wound healing process of superficial wounds in diabetic BALB/c mice. A potency test was performed to confirm the batch of ICRP, and then its parts were separated into pellets, supernatants, and exosomes, and another group of exosomes loaded with insulin was added. Viability and scratch healing were assessed in NIH-3T3, HUVEC, and HACAT cell lines. Diabetes was induced with streptozotocin, and wounds were made by dissecting the back skin. Treatments were topically applied, and closure was monitored; inflammatory cytokines in sera were also evaluated by flow cytometry, and histological analysis was performed by Masson’s staining and immunohistochemistry for p-AKT, p-FOXO, p-P21, and p-TSC2. ICRP pellets and exosomes increased cellular viability, and exosomes and exosome–insulin accelerated scratch healing in vitro. Exosome–insulin releases insulin constantly over time in vitro. In vivo, treatments accelerated wound closure, and better performance was observed in pellet, exosome, and exosome–insulin treatments. Best collagen expression was induced by ICRP. P-AKT and p-FOXO were overexpressed in healing tissues. Inflammatory cytokines were downregulated by all treatments. In conclusion, IMMUNEPOTENT CRP components, especially exosomes, and the process of encapsulation of exosome–insulin accelerate diabetic wound healing and enhance cellular proliferation, collagen production, and inflammation modulation through the phosphorylation of components of the AKT pathway.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Exosomes isolated from IMMUNEPOTENT CRP, a hemoderivative, to accelerate diabetic wound healing

García Coronado,

Franco Molina,

Zárate Triviño

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…IMMUNEPOTENT CRP ® is a bovine dialyzable leukocyte extract. Our research group has published extensive research about IMMUNEPOTENT CRP's antioxidant, antitumor and anti-inflammatory properties at in vitro, preclinical and clinical levels [12][13][14][15]. However, the classical preparation process of the bDLE IMMUNEPOTENT CRP ® presents some challenges for the establishment of a production line.…”

Section: Discussionmentioning

confidence: 99%

Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT CRP: Evaluation of Biological Activity of the Modified Product

et al. 2021

Self Cite

View full text Add to dashboard Cite

Dialyzable leukocyte extracts are clinically used under different commercial names (IMMUNEPOTENT CRP®, IMMODIN®, Transferon®) to modulate the immune response altered by pathological conditions such as cancer, inflammation, and viral infections. The purpose of this study is to improve the production process of bovine dialyzable leukocyte extract without decreasing its biological activities (antioxidant, anti-inflammatory, and antitumoral). Our product modification consists of adding a dry heating step in the production process. In this study, we evaluated and compared the chemical composition (bromatological analysis), physical structure (infrared spectroscopy, X-ray diffraction, SEM, and zeta potential) and biological function of the dialyzable leukocyte extracts obtained from fresh and dry bovine spleens. Our results showed that the use of a drying step in the production process of the bovine dialyzable leukocyte extract (bDLE) did not affect its antioxidant and anti-inflammatory effects and it improved its antitumor properties. We suggest that this process modification could be applied to other biological products, such as dialyzable leukocyte extracts derived from other sources, in order to improve its functionality and formulation.

show abstract

“…Procedures for salivary collection are less invasive, easy, require no special equipment and / or trained staff, and are more convenient for patients than those of blood samples. 34,35 The measurement results of two observations showed the TNF-α expressions were found maximum on day 1 after odontectomy. Elevated serum and tissue levels of TNF-α are found in inflammatory conditions.…”

Section: Original Researchmentioning

confidence: 98%

“…Assessment of the inflammatory response caused by proinflammatory cytokines (TNF-α) used saliva as diagnostic fluid as Franco-Molina et al 34 used in their study. Saliva is representative fluid originating from the local environment around the surgical area.…”

Section: Original Researchmentioning

confidence: 99%

Effects of 15 mg meloxicam administered before odontectomy on pain, facial edema, trismus, and expressions of TNF following odontectomy of impacted mandibular third molar

Ruth

Hasan

Rahardjo

et al. 2020

J Dentomaxillofac Sci

View full text Add to dashboard Cite

Objective: To evaluate the effects of 15 mg meloxicam administered 60 minutes before odontectomy on pain, facial edema, trismus and expressions of TNF-α after odontectomy of impacted mandibular third molar. Material and Methods: A total of 24 patients were randomized into treatment groups, each with 12 patients: Group A was administered with 15 mg of meloxicam; and Group B with placebo. Drugs were administered orally 60 minutes prior to surgery. Observation of pain (seen from VAS scores), facial edema (seen from swollen cheeks), trismus (seen from mouth opening) and expressions of TNF-α (measured from saliva by ELISA method), performed before odontectomy, H+1 (24 hours after odontectomy) and H+3 (72 hours after odontectomy).Results: Patients who received 15 mg meloxicam 60 minutes before odontectomy showed less postoperative pain (p=0.000), less facial edema (p=0.000) and lower expressions of TNF-α (p=0.000). No differences were found in mouth opening between the meloxicam group and placebo group (p=0.522). The higher level of TNF-α level will lead to higher level of pain, greater facial edema and causes smaller mouth opening. Conclusion: Oral administration of 15 mg meloxicam 60 minutes prior to odontectomy was found more effective in reducing pain, facial edema and expressions of TNF-α after odontectomy of impacted mandibular third molar compared with placebo.

show abstract

Clinical trial evaluating the effectiveness of biocompound IMMUNEPOTENT CRP in the third-molar extraction

Cited by 6 publications

References 26 publications

Exosomes isolated from IMMUNEPOTENT CRP, a hemoderivative, to accelerate diabetic wound healing

Exosomes isolated from IMMUNEPOTENT CRP, a hemoderivative, to accelerate diabetic wound healing

Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT CRP: Evaluation of Biological Activity of the Modified Product

Effects of 15 mg meloxicam administered before odontectomy on pain, facial edema, trismus, and expressions of TNF following odontectomy of impacted mandibular third molar

Contact Info

Product

Resources

About